Editas Medicine Inc. (NASDAQ: EDIT) presented preclinical data on its gene editing candidate EDIT-401 for hyperlipidemia treatment at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE